Government Agencies

Pharmalot By Ed Silverman

HHS withdraws 340B drug discount opinion amid lawsuits by pharma companies

First Opinion By Dan Troy

3D bioprinting can help end organ transplant waitlists — if the FDA stops delaying

Pharmalot By Ed Silverman

Billions spent on prescription drug ads may have increased Medicare spending

First Opinion By Madhav Thambisetty

Why a controversial decision won’t stop me from serving on FDA advisory committees

Politics By Rachel Cohrs

Biden administration moves to axe Trump 340B rule targeting community clinics

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Every angle on the FDA’s polarizing approval of Biogen’s Alzheimer’s drug

Biotech By Adam Feuerstein

Virtual Event: The ASCO Recap, Live!

Speaker Pelosi Introduces Flagship Prescription Drug Costs Bill

Politics By Nicholas Florko

Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate

Health By Andrew Joseph

An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug

Pharmalot By Ed Silverman

‘The price is bewildering’: The cost of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks

Matt's Take By Matthew Herper

By approving Biogen’s Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk

The Readout LOUD By Damian Garde and Adam Feuerstein

Listen: Fauci’s emails, FDA kremlinology, & covering the CRISPR babies scandal

First Opinion By Brian Barnett, Rick Doblin, and Julie Holland

NIH: It’s time to make your mark on the renaissance of medicinal psychedelics

Pharmalot By Ed Silverman

FTC issues a non-committal report on ‘rebate walls,’ but will the agency dig deeper?

The Readout LOUD By Adam Feuerstein, Damian Garde, and Meg Tirrell

Grilling Scott Gottlieb on burgers, drugs, and a post-pandemic summer

Pharmalot By Ed Silverman

FDA revives a controversial program the Trump administration ended over ‘inaccuracies’

First Opinion By George Vradenburg and Ellen V. Sigal

Created correctly, the Advanced Research Projects Agency for Health will accelerate medical innovation

Pharmalot By Ed Silverman

Drug makers argue an HHS rule would penalize them for offering co-pay coupons

Health Tech By Katie Palmer

Health tech companies form a new coalition to advance the role of real-world data

Politics By Nicholas Florko

Democrats call on FTC to investigate AbbVie’s Humira pricing strategy

Pharmalot By Ed Silverman

Feds tell drug makers to offer discounts to safety-net hospitals or face penalties

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Lessons from a botched pandemic response, CDC sluggishness, & the future of health tech

Health By Nicholas Florko

CDC’s slow, cautious messaging on Covid-19 seems out of step with the moment, public health experts say

Opinions+ By Tonya Winders

Faster approval of complex generics is central to affordable, equitable care

Pharmalot By Ed Silverman

Most Read

Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision

FDA accuses company of distributing unapproved Covid test and using falsified data

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

NIH releases a plan to confront structural racism. Critics say it’s not enough

FDA says it will ban all menthol cigarettes and flavored cigars

The CDC’s latest blunder is really about trust, not masks

Former FDA chief Hahn defends his jump to Flagship Pioneering, the firm behind Moderna

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

All Coverage

HHS withdraws 340B drug discount opinion amid lawsuits by pharma companies

3D bioprinting can help end organ transplant waitlists — if the FDA stops delaying

Billions spent on prescription drug ads may have increased Medicare spending

Why a controversial decision won’t stop me from serving on FDA advisory committees

Biden administration moves to axe Trump 340B rule targeting community clinics

Listen: Every angle on the FDA’s polarizing approval of Biogen’s Alzheimer’s drug

Virtual Event: The ASCO Recap, Live!

Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate

An extra twist in the FDA’s Alzheimer’s decision: no limits on which patients can get the drug

‘The price is bewildering’: The cost of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks

By approving Biogen’s Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk

Listen: Fauci’s emails, FDA kremlinology, & covering the CRISPR babies scandal

NIH: It’s time to make your mark on the renaissance of medicinal psychedelics

FTC issues a non-committal report on ‘rebate walls,’ but will the agency dig deeper?

Grilling Scott Gottlieb on burgers, drugs, and a post-pandemic summer

FDA revives a controversial program the Trump administration ended over ‘inaccuracies’

Created correctly, the Advanced Research Projects Agency for Health will accelerate medical innovation

Drug makers argue an HHS rule would penalize them for offering co-pay coupons

Health tech companies form a new coalition to advance the role of real-world data

Democrats call on FTC to investigate AbbVie’s Humira pricing strategy

Feds tell drug makers to offer discounts to safety-net hospitals or face penalties

Listen: Lessons from a botched pandemic response, CDC sluggishness, & the future of health tech

CDC’s slow, cautious messaging on Covid-19 seems out of step with the moment, public health experts say

Faster approval of complex generics is central to affordable, equitable care

Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year

government agencies

Most Read

All Coverage